Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CureVac N.V (CVAC) EBITDA Margin: 2019-2025

Historic EBITDA Margin for CureVac N.V (CVAC) over the last 4 years, with Jun 2025 value amounting to -24.50%.

  • CureVac N.V's EBITDA Margin rose 47802.00% to -24.50% in Q2 2025 from the same period last year, while for Jun 2025 it was -0.07%, marking a year-over-year increase of 29168.00%. This contributed to the annual value of 33.20% for FY2024, which is 54328.00% up from last year.
  • According to the latest figures from Q2 2025, CureVac N.V's EBITDA Margin is -24.50%, which was down 195.63% from -8.29% recorded in Q1 2025.
  • In the past 5 years, CureVac N.V's EBITDA Margin registered a high of 0.27% during Q4 2024, and its lowest value of -1,133.60% during Q1 2021.
  • For the 3-year period, CureVac N.V's EBITDA Margin averaged around -309.60%, with its median value being -160.01% (2023).
  • As far as peak fluctuations go, CureVac N.V's EBITDA Margin spiked by 107,167bps in 2022, and later tumbled by 74,350bps in 2023.
  • Over the past 5 years, CureVac N.V's EBITDA Margin (Quarterly) stood at -0.08% in 2021, then tumbled by 111bps to -1.19% in 2022, then skyrocketed by 89bps to -0.30% in 2023, then skyrocketed by 57bps to 0.27% in 2024, then spiked by 47,802bps to -24.50% in 2025.
  • Its EBITDA Margin was -24.50% in Q2 2025, compared to -8.29% in Q1 2025 and 0.27% in Q4 2024.